Peptic Ulcer Drugs Market

The global Peptic Ulcer Drugs Market is estimated to be valued at USD 37.4 billion in 2026 and is projected to reach USD 47.4 billion by 2033, expanding at a CAGR of 3% during the forecast period from 2026 to 2033.

Growing Prevalence of Peptic Ulcers due to Increasing Helicobacter pylori Infection Drives Peptic Ulcer Drugs Market

Infection with a bacterium Helicobacter pylori and long-term use of pain relievers (NSAID use); including over-the-counter products containing aspirin, ibuprofen, and naproxen sodium, are causes of peptic ulcers. A rare medical condition can also cause a peptic ulcer. Drs. Barry Marshall and J. Robin Warren were awarded the 2005 Nobel Prize in Medicine for their discovery of a bacterial cause of peptic ulcer disease. One of the key driving factors for the peptic ulcer drugs market has been the growing prevalence of peptic ulcers across the globe. Unhealthy lifestyles remain the primary causes of the rise in peptic ulcer cases and, therefore, the market expansion. Another major factor driving the growth of the global peptic ulcer medicines space is patients' rising preference for peptic ulcer curative pharmaceuticals over surgery.

Stress, drug-induced ulcers, an increased risk of infection by H. pylori, evolving dietary habits, increased cancer prevalence, and exploding cigarette and alcohol usage are the key driving factors for the peptic ulcer drugs market. A peptic ulcer is a serious medical condition. According to a study, over 4 million people in the United States suffer from peptic ulcers each year. The growing 6number of people with peptic ulcers will drive the demand for peptic ulcer drugs in the coming years. Peptic ulcer disease primarily affects the elderly, with the peak incidence occurring between 55 and 65. As a result, in addition to the increased frequency of peptic ulcer disease, a growing geriatric population is likely to be accelerating the rise of peptic ulcer drugs market through the forecast period. According to the UN Database on World Population Ageing 2020, the global geriatric population will expand from 727 Mn in 2020 to 1.5 Bn by 2050. As a result of the growing aging population, the prevalence of peptic ulcers due to H. pylori bacterium or anti-inflammatory medication would rise, driving the growth of peptic ulcer drugs market.

Antibiotics Represent the Dominant Segment with Growing Prevalence of H. pylori Infection

In the forecast period, the antibiotics sector will dominate the global peptic ulcer drugs market. The Helicobacter pylori infection causes the most of peptic ulcer illnesses. The triple therapy that comprises two antibiotics, and one proton pump inhibitor, is the first-line treatment for this infection. The increased prevalence of infectious diseases, combined with supportive government regulations, is driving the sector. Increased antibiotic resistance infections due to antibiotic abuse or overuse will likely change prescription trends toward innovative medicines to treat bacterial infections. The growing disease burden is forcing governments and non-governmental organisations to invest in R&D activities and accelerate the development of novel antibiotics, as well as supportive regulatory measures to expedite the approval process and research financing. As a result, antibiotics have become more widely used, eventually leading to their dominance.

Increased Use of NSAIDs Accounts for North America’s Lead in Peptic Ulcer Drugs Market

North America will lead the global peptic ulcer drugs market share in the forecast period, and this trend is predicted to continue. According to a Harvard University study, over 4 million people in the United States suffer from peptic ulcers each year. The region's mature healthcare market is primarily driving the regional segment growth. The increased spending on creating novel and innovative treatments, research, and development efforts also drive North America's growth. The increased usage of nonsteroidal anti-inflammatory medications (NSAIDs) such as aspirin and greater awareness about treatment options for peptic ulcers are likely to fuel the expansion of the North American peptic ulcer pharmaceuticals market. According to the American Gastroenterological Association, more than 30 million Americans use NSAIDs daily to relieve headaches, sprains, arthritis, and other pains. The growing use of NSAIDs in the country will help to drive the peptic ulcer drugs market in the region.

Participants in the market are introducing new products and forming collaborations, alliances, and partnership agreements. In May 2020, The FDA approved RHB-105, a three-drug combination of omeprazole, amoxicillin, and rifabutin in one capsule that effectively eradicates Helicobacter pylori infection in adults, developed by researchers at the Michael E. De-Bakey Veterans Affairs Medical Center. In March 2020, RedHill Biopharma announced the commercial introduction of Talicia, a capsule used to treat H. pylori infection in patients in the United States. The major pharmaceutical company's announcement is expected to boost its market position shortly.

Key Market Companies

• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Abbott Laboratories
• AstraZeneca plc.
• Cadila Healthcare Ltd.
• Boehringer Ingelheim GmbH
• Eisai Co. Ltd.
• Yuhan Corporation
• GlaxoSmithKline plc.
• RedHill Biopharma

Global Peptic Ulcer Drugs Market is Differentiated as below:

By Product

• Proton Pump Inhibitors
• Potassium-Competitive Acid Blockers (P-CABs)
• Antacids
• H2-Antagonists
• Antibiotics
• Ulcer Protective

By Indication

• Gastritis
• Gastric Ulcers
• Duodenal Ulcers
• Gastroesophageal Reflux Disease (GERD)

By Distribution Channel

• Hospital Pharmacies
• Private Clinics
• Drug Stores
• Retail Pharmacies
• E-Commerce

By Regions

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa